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D-galactosamine plus LTD4,
3 suggesting that LTD4 is directlyCysteinyl-leukotrienes can cause cholestasis and liver dam-
involved in the mediation of liver damage.age when administered at nanomolar concentrations. Using
Previous studies from our laboratory and from otherthe isolated and perfused rat liver we analyzed whether S-
groups, using isolated and perfused rat liver, have shown thatadenosyl-L-methionine (SAMe) may protect this organ against
the administration of leukotriene C4 or LTD4, at nanomolarthe noxious effects of leukotriene-D4 (LTD4). We observed
concentrations, increases the perfusion pressure and inducesthat a 2 nmol bolus of this compound decreased bile flow
cholestasis.4-6 Very little is known on the mechanism under-(012.6% { 1.6%, P  .02), and bile salt excretion (023.5%
lying the cholestatic effect of cLTs, and, although leuko-{ 2.2%, P .02; both compared with baseline values), caused
trienes are thought to be implicated in the cholestasis accom-the release of glutamic-oxaloacetic transaminase (GOT) and
panying sepsis and inflammatory processes,7,8 there are fewlactic dehygrogenase (LDH) to the hepatic effluent, and in-
data on substances that can protect the liver against the cho-creased significantly the perfusion pressure as compared with
lestatic and toxic effects of cLTs.a control group not receiving LTD4 (6.0 { 1.1 vs. 0.2 { 0.02
S-adenosyl-L-methionine (SAMe) is a naturally occurringmm hg, respectively; P .001). The cholestatic effect of LTD4
metabolite that originates from methionine and adenosinewas attenuated by infusion of SAMe which, at rates of 67
triphosphate through the SAMe synthetase pathway.9 It hasand 100 mg/min, totally prevented the decrease in bile salt
been shown that SAMe has a protective role in experimentalexcretion. Likewise, in SAMe infused livers, the release to the
cholestasis induced by alcohol,10 acetaminophen,11 D-galac-effluent of GOT and LDH was lower than in the group receiv-
tosamine,12 carbon tetrachloride,13 or ethinyl estradiol.14 Ining LTD4 only, and was even lower than in the control group.
this study we analyze whether SAMe may alleviate the chole-We also found that the increase in perfusion pressure induced
static, cytotoxic, and hemodynamic effects induced by LTD4by LTD4 was prevented by SAMe in a dose-dependent manner.
on the isolated and perfused rat liver.Of interest, SAMe increased the biliary excretion of the eicosa-
noid in a dose-related fashion. We conclude that SAMe reverts
MATERIALS AND METHODSthe cholestatic, cytotoxic, and hemodynamic effects of LTD4
on the liver, and that these protective effects might be partly SAMe was a gift from Europharma (Madrid, Spain). Taurocholic
because of a stimulation of the biliary excretion of the leuko- acid (sodium salt), methionine, and bovine serum albumin were
obtained from Sigma Chemical Co. (St. Louis, MO). Synthetic stan-triene. (HEPATOLOGY 1997;26:330-335.)
dards of cLTs were from Cayman Chemical (Ann Arbor, MI), and
[3H]LTD4 was from Amersham (Little Chalfont, UK). ScintillationCysteinyl-leukotrienes (cLTs), specifically leukotriene C4 liquid (Normascint F-1) and methanol (high-performance liquid
and leukotriene D4 (LTD4), have been associated with the chromatography [HPLC] grade) were obtained from Scharlau (Bar-
induction of liver injury.1 A significant increase in the pro- celona, Spain). All other chemicals were purchased from Merck
duction of cLTs occurs in some experimental models of (Darmstadt, Germany).
Livers were isolated from male Wistar rats (range, 240-255 gfulminant hepatitis, as those induced by frog virus 32 or D-
body weight), and they were used in a recirculating antegrade perfu-galactosamine plus endotoxin.3 Moreover, a fulminant hepa-
sion system. Liver isolation was as previously described.4 Briefly,titis similar to that induced by administration of D-galactos-
the bile duct was first cannulated with a polyethylene tubing PE-50,amine plus endotoxin can be induced by administration of
followed by cannulation of the portal vein with a catheter Abbocath
(Abbott, Sligo, Ireland) 16-G. Then, the liver was perfused in situ
with oxygenated and heparinized Krebs-Ringer bicarbonate (KRB)
buffer at 377C, the vena cava was cut, and the thoracic vena cava wasAbbreviations: cLTs, cysteinyl-leukotrienes; LTD4, leukotriene D4; SAMe, S-adeno-
cannulated with a polyethylene cannula (1.5 mm inner diameter),syl-L-methionine; KRB, Krebs-Ringer bicarbonate; RP-HPLC, reverse-phase high-per-
formance liquid chromatography; GOT, glutamic-oxaloacetic transaminase; LDH, lactic defining the final path of perfusion from vena porta to vena cava.
dehydrogenase. At that moment, the liver was transferred to an acrylic platform,
From the Department of Medicine and Liver Unit, University Clinic and Medical and placed into a thermostatized and humidified chamber. The liver
School, University of Navarra, Pamplona, Spain. was perfused at 377C with 250 mL of KRB buffer (116 mmol/L
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at a rate of 30 mL/min. Oxygenation was guaranteed by gassing theFax: 34-48-296-785.
perfusion liquid with 95% O2, 5% CO2. The pH of the mediumCopyright q 1997 by the American Association for the Study of Liver Diseases.
0270-9139/97/2602-0013$3.00/0 was adjusted at 7.35-7.40 by an automatic autoburette (Radiometer,
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Copenhagen, Denmark), and the perfusion pressure was continu-
ously registered with a pressure transducer (Letica, Barcelona,
Spain). Animals were treated avoiding unnecessary suffering, and
in accordance with the guidelines of our institution.
The design of the experiments was the following. After a 50-
minute stabilization period, and a further 30-minute basal period,
a bolus of 2 nmol of LTD4 (or 500 mL of KRB buffer in the control
group) was injected, and the experiment was continued for another
30 minutes (experimental period).
Five groups of perfused livers were studied: control group (KRB
buffer injection in minute 80; n  6); LTD4 group (injection of 2
nmol of LTD4 in minute 80; n  7); and three SAMe-treated LTD4
groups (n  6-7 experiments in each group), in which SAMe was
continuously infused from minute 0 onwards at rates of 33, 67, or
100 mg/min (equivalent to 63, 127, and 190 nmol/min) and LTD4
was administered as indicated above. An additional group was in-
cluded, in which 190 nmol/min of methionine (equimolar with the
high dose of SAMe) were infused since minute 0 and LTD4 was
injected in minute 80, to check the specificity of SAMe.
Also, we studied the hepatic metabolism of the exogenously
added LTD4, and the effect of the continuous infusion of SAMe, at
the three same rates as before, on such metabolism. Thus, four
additional groups of livers were analyzed (n  3 to 5 experiments).
In one of them, which served as a control group, a bolus of [3H]LTD4
(5.8 1 10012 mol/g liver) was injected at minute 50. In the other
three groups, the same amount of [3H]LTD4 was injected at minute
50, and a continuous infusion of SAMe at 33, 67, or 100 mg/min
was maintained from minute 0 onwards. Bile and perfusate fractions
were collected every 10 minutes starting at minute 50, and the
radioactivity present in these fractions was counted in a scintillation
counter (LKB, Turku, Finland). Furthermore, in the groups in
which [3H]LTD4 alone or plus 100 (mg/min of SAMe was injected,
we performed RP-HPLC separation of the bile fractions collected, FIG. 1. (A) Bile flow and (B) biliary bile salt excretion in control livers
to check the metabolic fate of LTD4 and the effect of SAMe on this and in livers treated with LTD4 alone or LTD4 plus continuous infusion of
metabolism. SAMe at three different doses (33, 67, or 100 mg/min). Arrows indicate the
time at which LTD4 (2 nmol) or KRB vehicle (in control group) was injected.RP-HPLC of the biliary metabolites of [3H]LTD4 was performed
The data represent the mean of six to seven separate experiments in eachon a Nova Pak column (10 1 0.4 cm, 5-mm particles, Waters,
group; values corresponding to this figure have been represented in TablesMilford, MA). The mobile phase consisted of methanol, water, and
1 and 2. *P  .01 and **P  .001 in respect to the basal value (minuteacetic acid (65/35/0.1 by volume) at pH 5.6. In these conditions,
80).the retention times of main leukotrienes were: LTC4  5 minutes,
LTD4  9 minutes, LTE4  11 minutes, and N-acetyl-LTE4  7
minutes. Twenty-second fractions of the HPLC eluent were col-
lected and then counted in a LKB scintillation counter.
effect of LTD4 (mean reduction in the three groups infusedIn all experimental groups, a continuous infusion of sodium
with SAMe: 04.8% { 0.4%, P  .001 with respect to thetaurocholate (40 mmol/h) was also maintained throughout the ex-
LTD4 group) (Table 1).periments, to counteract the loss of bile salts.
Biliary excretion of bile salts in all groups of livers isTo assess the viability of the livers, samples of the hepatic effluent
(2.5 mL) were obtained every 10 minutes following the stabilization shown in Fig. 1B. There were no significant differences
period. In these samples, the levels of glutamic-oxaloacetic transam- between groups in samples corresponding to basal period,
inase (GOT), lactic dehydrogenase, and glucose were measured by although the highest values were found in the SAMe-treated
enzymatic conventional methods, and K/ concentration was deter- livers. In control group, vehicle administration did not
mined in an automatic analyzer (Beckman, Palo Alto, CA). Also, modify the biliary excretion of bile salts. In contrast, LTD4the bile produced in these 10-minute periods was collected in pre-
(2 nmol) caused a significant decrease in bile salt excretionweighted polypropylene tubes. Bile flow was calculated by gravime-
(mean reduction in the three experimental periods: 023.5try (assuming a bile density 1), and total bile salts were quantified { 2.2%, P  .02 with respect to the basal value). Infusionby the 3a-hydroxysteroid dehydrogenase method.
of SAMe was effective in preventing the LTD4 -induced re-Mann-Whitney, Wilcoxon, and Kruskal-Wallis nonparametric
statistical tests were used for comparisons between experimental duction in bile salt excretion. Thus, in the group infused
groups.15 Values are expressed as the mean { SEM. with 100 mg/min of SAMe, the levels of biliary bile salts
after LTD4 injection were significantly higher than those
RESULTS in livers from rats treated with only LTD4 . Infusion with
33 or 67 mg/min of SAMe also diminished the cholestaticBile flow throughout the experiments is represented in
effect of LTD4, but the differences in bile salt excretionFig. 1A. As it can be seen, in control group vehicle adminis-
with the group receiving only LTD4 were not significanttration did not modify the levels of bile flow. In contrast,
(Table 2). Methionine infusion at a concentration equiva-administration of 2 nmol of LTD4 induced a significant drop
lent to the highest one of SAMe (190 nmol/min), also pre-in bile flow with respect to the basal values in the three
vented the cholestatic effects of LTD4 . Thus, the decreasesexperimental periods (mean decrease: 012.6% { 1.6%, P 
.02). Continuous infusion of SAMe attenuated the cholestatic in bile flow (05.87% { 2.2%), and in biliary bile salt excre-
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TABLE 1. Bile Flow Along the Experiments in All Groups (mL/min/g Liver)
Basal Period Experimental Period
Group Minute 60 Minute 70 Minute 80 Minute 90 Minute 100 Minute 110
Control 1.79 { 0.13 1.76 { 0.13 1.79 { 0.14 1.80 { 0.14 1.82 { 0.15 1.81 { 0.15
LTD4 1.96 { 0.17 1.86 { 0.14 1.87 { 0.13 1.65 { 0.11* 1.64 { 0.13* 1.62 { 0.14*
LTD4 / SAMe (33 mg/min) 2.18 { 0.13 2.04 { 0.10 1.95 { 0.10 1.81 { 0.10* 1.84 { 0.09* 1.86 { 0.09*
LTD4 / SAMe (67 mg/min) 1.99 { 0.08 1.87 { 0.08 1.81 { 0.08 1.73 { 0.09* 1.77 { 0.08* 1.81 { 0.08
LTD4 / SAMe (100 mg/min) 2.19 { 0.14 2.04 { 0.11 2.00 { 0.11 1.88 { 0.10* 1.86 { 0.10* 1.85 { 0.10*
NOTE. After 50 minutes of stabilization and 30 minutes of basal period, a bolus of KRB (in control group), or 2 nmol LTD4 (in the other groups),
was injected (minute 80). In SAMe-treated groups, a continuous infusion of SAMe was maintained from minute 0 onwards. Bile and hepatic effluent were
collected every 10 minutes.
* P  .05, as compared with the value of the same group at minute 80.
tion (03.42% { 3.9%) were not significantly different from Continuous infusion of SAMe did not prevent the initial rise
of the perfusion pressure, but reduced both the intensity andthose found in control group.
As shown in Fig. 2, the release of hepatocyte enzymes to the length of the second wave of increased pressure in a dose-
related manner (Fig. 3). Thus, during this second periodthe effluent increased after LTD4 administration, as compared
with control group (Fig. 2). When LTD4 injection was given (between 4 and 20 minutes after LTD4 injection) the maxi-
mum increase of the perfusion pressure in the groups infusedto SAMe-infused livers, the hepatic release of GOT and lactic
dehydrogenase (LDH) was lower than in livers receiving with 33, 67, or 100 mg/min of SAMe was respectively: 4.2 {
1.1, 3.2 { 0.3, and 1.4 { 0.7 mm hg, the last value beingLTD4 alone. Moreover, in livers treated with SAMe and LTD4
the release of GOT was even lower than in the control group, significantly lower (P  .01) than that found in the group
that received only LTD4. In the livers receiving a continuousthus indicating that SAMe not only protects the liver against
the cytotoxic effects of cLTs but improves the viability of the infusion of 190 nmol/min of methionine, values of 4.3 { 0.3
mm hg were observed during the second wave of increasedorgan in our system. On the other hand, when 190 nmol/
min of methionine were infused instead of SAMe, the release pressure; these values were not significantly different from
those obtained in the group that received LTD4 aloneof GOT to the hepatic effluent was similar to that measured
in the control group (values at the end of the experiment: (Fig. 3).
Because, as indicated above, SAMe appeared to block a93.3 { 11.3 vs. 81.5 { 11.4 mIU/min/g liver, respectively;
nonsignificant), whereas the levels of LDH at the end of the diversity of effects of LTD4 in the liver, we performed addi-
tional experiments to establish whether SAMe might blockexperiment in the methionine group were between those
found in control group and in LTD4 group (1.56 { 0.29, 1.02 the uptake of LTD4 by liver cells or whether it could affect
the transport and biliary elimination of this compound. To{ 0.31, and 2.26 { 0.64 IU/min/g liver, respectively; n.s.).
As shown in Fig. 3, in the control group the injection of this aim we analyzed the metabolism and biliary excretion
of exogenously added [3H]LTD4 and the effect on these pro-the vehicle was followed by a very small (1.1 { 0.1 mm hg)
and short-lasting ( 1 minute) increase in the perfusion cesses of SAMe infusion at three different rates. As it can be
seen in Fig. 4 A, SAMe caused an increase in the biliarypressure. In contrast, after 2 nmol bolus injection of LTD4,
the perfusion pressure in the group that was not receiving excretion of radioactivity, in a dose-dependent manner. This
finding was associated with a dose-dependent reduction inSAMe changed following a different pattern: during the first
minute after LTD4 injection, there was a quick rise of 4.8 { the radioactivity remaining in the perfusate (Fig. 4B), indicat-
ing that SAMe might facilitate the clearance of leukotrienes0.8 mm hg (P  .01 as compared with the control group);
3 to 4 minutes later, the pressure returned to levels close to by increasing the biliary excretion of these compounds.
To examine the metabolic fate of injected [3H]LTD4 ,basal values, and then increased again to values significantly
greater than those observed in the control group (6.0 { 1.1 and the effect of SAMe on this metabolism, RP-HPLC frac-
tionation of biliary metabolites of [3H]LTD4 was per-vs. 0.2 { 0.02 mm hg, respectively; P  .001). This second
wave of increased pressure lasted for more than 15 minutes. formed. As represented in Fig. 5, the HPLC profile of radio-
TABLE 2. Biliary Excretion of Bile Salts Along the Experiments in All Groups (nmol/min/g Liver)
Basal Period Experimental Period
Group Minute 60 Minute 70 Minute 80 Minute 90 Minute 100 Minute 110
Control 25.2 { 3.9 28.8 { 1.4 28.6 { 1.8 28.1 { 2.5 26.5 { 1.3 27.9 { 3.3
LTD4 28.6 { 3.0 27.3 { 2.8 28.9 { 2.6 22.0 { 2.3† 22.3 { 2.6† 22.4 { 2.4†
LTD4 / SAMe (33 mg/min) 29.3 { 2.0 29.7 { 2.2 30.1 { 2.0 26.7 { 2.2† 26.9 { 2.0* 29.7 { 2.6
LTD4 / SAMe (67 mg/min) 33.2 { 2.1 32.7 { 2.3 31.3 { 1.6 29.6 { 1.8 32.8 { 2.2 32.5 { 1.9
LTD4 / SAMe (100 mg/min) 30.2 { 1.2 30.6 { 1.2 31.3 { 1.5 30.4 { 1.1‡ 31.3 { 1.2‡ 32.7 { 1.2‡
NOTE. Experimental groups correspond to those described in Table 1.
* P  .05 and †P  .02 as compared with the value of the same group at minute 80.
‡ P  .05 in respect to the same time of group LTD4.
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pared with SAMe, induces only a partial protection against
leukotrienes.
The observation that cLTs, at nanomolar concentration,
induce a reduction in bile flow has been reported by others.6
The effect of LTD4 on bile flow and on bile salt excretion
found in the present study is similar to that previously re-
ported by our group using LTC4 in the same experimental
model.4 The mechanisms through which cLTs induce chole-
stasis are not clear. Although it has been proposed16 that
cLTs can cause fluid extravasation and edema around bile
ducts, thus impairing bile flow, our finding that cLTs reduce
bile salt excretion suggests that these substances affect bile
salt kinetics.4 Because cLTs do not impair sinusoidal uptake
nor canalicular excretion of bile salts,17-20 it seems possible
that they might influence intrahepatocytic transport of bile
salts, as we have previously suggested.4
SAMe has been shown to improve bile flow and bile salt
excretion in experimental models of cholestasis produced by
ethynylestradiol or total parenteral nutrition in the rat,14,21,22
and similar effects have been observed in the present work
in LTD4-induced cholestasis. The increase in bile flow ob-
served in SAMe-treated livers could be mediated, at least in
part, by a ‘‘solvent drag’’ effect, but SAMe has also been
reported to improve both Na//K/-ATPase activity and mem-
brane fluidity of hepatocytes in experimental cholestasis,14,22
being these factors involved in solute transport across the
hepatocellular membrane. In addition to these effects, the
present report shows that SAMe increases the biliary excre-
tion of LTD4 and its metabolites in a dose-dependent mannerFIG. 2. Hepatic release to the effluent of (A) GOT and (B) LDH through-
(Figs. 4 and 5). The enhanced elimination of cLTs to bileout the experiments, as described in legend of Fig. 1. The data represent
might reduce the intracellular levels of these toxic com-the mean of six to seven separate experiments in each group. Arrows indicate
the time at which LTD4 (2 nmol) or KRB vehicle (in control group) was pounds and this would contribute to explain the antichole-
injected. a, P  .01 with respect to the SAMe-treated groups; b, P  .01 static activity of SAMe in our experimental model.
with respect to the rest of the groups; c and d, P  .05 and P  .01,
As shown in previous reports23 and in the present study,respectively, in comparison with the control group; e, P  .05 with respect
to the SAMe-treated groups; and f, P  .05 with respect to the groups
infused with 67 or 100 mg/min of SAMe.
activity in bile samples from livers that received [3H]LTD4
at minute 50 (left column), was similar to that found in
bile samples from livers receiving a continuous infusion
of 100 mg/min of SAMe and [3H]LTD4 at minute 50 (right
column). In both groups the main radioactive peak corre-
sponded to nonmetabolized [3H]LTD4 (minute 9), being
[3H]N-Ac-LTE4 ( minute 7) the principal LTD4 metabo-
lite detected.
DISCUSSION
In the isolated and perfused rat liver, we show that a bolus
injection of 2 nmol of LTD4 causes reduction in bile flow
and bile salt excretion, increased release of GOT and LDH
to the effluent and a rise in the perfusion pressure. All these
changes are significantly attenuated, or totally reversed, by
SAMe. The effects of SAMe are not totally paralleled by its
FIG. 3. Changes in perfusion pressure over baseline value in the experi-precursor methionine that was capable of reducing the chole-
mental period in control livers, in livers treated with LTD4 alone, in liversstatic effects of LTD4, but only partially protected against treated with LTD4 plus continuous infusion of SAMe at three different doses
the cytotoxic and hemodynamic effects of this compound. It (33, 67, or 100 mg/min), and in livers treated with LTD4 plus continuous
infusion of 190 nmol/min of methionine (equimolar to the highest dose ofshould be considered that methionine is a precursor of SAMe,
SAMe). Arrow indicates the time at which LTD4 (2 nmol) or vehicle (inbut the synthesis of this substance consumes adenosine tri-
control group), was injected. Previously, perfusion pressure was similar inphosphate.9 These two effects (on antioxidant cell defenses all groups. The data represent the mean of six to seven separate experiments.
on one hand, and on cell energy stores on the other) could * P  .01, with respect to LTD4-treated group; and ** P  .001, with
respect to the control group.provide an explanation for the fact that methionine, as com-
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in the isolated and perfused liver: a sharp and short peak
of increased pressure occurring immediately after the bolus
injection of LTD4, and a lasting wave of increased pressure
starting approximately 3 minutes after the end of the first
peak (Fig. 3). The sequential changes of pressure here re-
ported have not been previously recognized, possibly because
other studies have used continuous infusion of the eicosa-
noid,5,6,17 instead of bolus injection. In our study, the first
peak is probably caused by the vasoconstrictor action of LTD4
on hepatic vasculature,27,28 whereas the second wave of in-
creased pressure could be caused by other as yet uncharacter-
ized actions of cLTs on the hepatic parenchyma and/or vascu-
lature.
SAMe infusion did not prevent the first increase in perfu-
sion pressure induced by LTD4, but reduced the second peak
in a dose-dependent manner (Fig. 3). Because vascular endo-
thelium and hepatocytes possess specific receptors for
cLTs,29,30 the different effect of SAMe on the first and second
peaks of pressure suggests that this substance does not block
the binding of cLTs to the cell receptor, but inhibits later
metabolic events leading to the second wave of increased
pressure. Our experiments show that SAMe does not inhibit
the uptake of LTD4 by liver cells. On the contrary, it reduces
the radioactivity remaining in the perfusate after injection of
[3H]LTD4, and increases the transport of the compound to
bile. Thus, further studies are needed to clarify the effects of
cLTs on the intrahepatic vascular resistance. These studies
could be of relevance in the understanding of the pathophysi-
ology of portal hypertension.
Acknowledgment: We thank P. Alzuguren and R. Bilbao
for their technical assistance.
FIG. 4. Effect of SAMe infusion on the excretion of radioactivity in (A)
bile and in (B) perfusate. At minute 50, 5.8 1 10012 mol/g liver of [3H]LTD4
were injected in the isolated rat liver, and the radioactivity of both bile and
perfusate 10-minute fractions was counted. SAMe was infused from minute
0 onwards, at doses of 33, 67, and 100 mg/min. Arrow marks the time at
which [3H]LTD4 was administered. * P  .05 and ** P  .01 in respect to
the values in group in which only [3H]LTD4 was given.
cLTs at nanomolar doses affect liver cell viability as mani-
fested by increased release of GOT and LDH to the effluent.
This effect is prevented by SAMe infusions that are able to
reduce the release of enzymes to levels lower than those
found in the control group. This protective role for SAMe on
liver viability has also been observed in other experimental
models of hepatic injury. Thus, Stramentinoli et al. reported
that the administration of SAMe plus D-galactosamine re-
duced the serum levels of GOT to values close to controls,12
and Lieber et al. found similar results in a model of liver
injury induced by alcohol in baboons.24 It has been reported
that cLTs increase the hepatic efflux of glutathione,23 thus
reducing the intrahepatic levels of this antioxidant and detox-
ifying substance.25 In the LTD4 model of liver injury, SAMe
may have cytoprotective effects by at least two mechanisms:
by acting as a main precursor of glutathione through the FIG. 5. RP-HPLC extraction of radioactivity present in bile of livers that
transsulfuration pathway,26 and, as shown in the present received a bolus injection of 5.8 1 10012 mol/g liver of [3H]LTD4 at minute
50. Left column: livers perfused with KRB alone. Right column: livers per-work, by stimulating the biliary disposition of leukotrienes,
fused with KRB and 100 mg/min of SAMe. Only the radioactive profiles ofthus reducing the noxious effects of these compounds in the
bile samples corresponding to minute 70 (highest level of biliary radioactiv-liver. ity, see Fig. 4), minute 90, and minute 110 have been represented. The
Of interest, we found that administration of a bolus of scale in ordinates is different in each group to better compare the radioactive
profile.LTD4 determined a biphasic change of the perfusion pressure
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